J&J expects to file for approval of 11 drugs by 2015

05/26/2011 | Wall Street Journal, The · Reuters

Johnson & Johnson intends to submit 11 treatments for regulatory approval by 2015, the health care giant told analysts and investors. Among them are Alzheimer's disease medicine bapineuzumab and type 2 diabetes drug canagliflozin. "We are returning to growth, and we expect to outpace market growth," said Sheri McCoy, vice chairwoman and executive-committee member.

View Full Article in:

Wall Street Journal, The · Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ
Health Plan CEO – Oregon
Trillium Community Health Plan
Eugene, OR
Director of Operations - GBS
Mayo Clinic
Rochester, MN